Granulocyte-monocyte apheresis combination therapy after loss of response to anti-TNF drugs

被引：0
|
作者：
Rodriguez-Lago, I. [1 ]
Sempere, L. [2 ]
Gutierrez, A. [2 ,3 ]
Beltran, B. [4 ]
Saez, E. [4 ]
Hinojosa, E. [5 ]
Mora, M. [5 ]
Canete, F. [6 ]
Manosa, M. [6 ]
Khorrami, S. [7 ]
Ginard, D. [7 ]
Cabriada, J. L. [1 ]
机构：
[1] Hosp Galdakao, Gastroenterol, Galdakao, Spain
[2] Hosp Gen Univ Alicante, Gastroenterol, Alicante, Spain
[3] CIBEREHD Ctr Invest Biomed Red Area Temat Enferme, Alicante, Spain
[4] Hosp La Fe, Gastroenterol, Valencia, Spain
[5] Hosp Manises, Gastroenterol, Manises, Spain
[6] Hosp Badalona Germans Trias & Pujol, Gastroenterol, Badalona, Spain
[7] Hosp Son Espases, Gastroenterol, Palma de Mallorca, Spain
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P560
引用
收藏
页码：S389 / S389
页数：1
相关论文
共 50 条
  • [41] Demyelination After Anti-TNF Therapy: Who is at Risk?
    Williams, Isabelle
    Uhlig, Holm H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (12): : 1651 - 1652
  • [42] LOSS OF RESPONSE AFTER FIRST LINE ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PRATICAL APPROACH AND MANAGEMENT
    Guella, S.
    Scrivo, B.
    Calvaruso, V.
    Giuffrida, E.
    Busacca, A.
    Guida, L.
    Carrozza, L.
    Cappello, M.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S136 - S136
  • [43] IMMUNOMODULATOR WITHDRAWAL FROM ANTI-TNF THERAPY IS NOT ASSOCIATED WITH LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE
    Mahmoud, Remi
    Schultheiss, Johannes P.
    Louwers, Jonas M.
    van der Kaaij, Michiel T.
    van Hellemondt, Boris P.
    Mahmmod, Nofel
    van Boeckel, Petra G.
    Jharap, Bindia
    Fidder, Herma H.
    Oldenburg, Bas
    GASTROENTEROLOGY, 2022, 162 (07) : S184 - S184
  • [44] Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease
    Mahmoud, Remi
    Schultheiss, Hans-Paul
    Louwers, Jonas
    van der Kaaij, Michiel
    van Hellemondt, Boris
    Mahmmod, Nofel
    van Boeckel, Petra
    Jharap, Bindia
    Fidder, Herma
    Oldenburg, Bas
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (11) : 2577 - +
  • [45] Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
    Tanida, Satoshi
    Ozeki, Keiji
    Kanno, Takuya
    Katano, Takahito
    Sugimura, Naomi
    Nishie, Hirotada
    Iwasaki, Hiroyasu
    Tanaka, Mamoru
    Shimura, Takaya
    Kubota, Eiji
    Kataoka, Hiromi
    JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA, 2021, 13 (10-11): : 510 - 514
  • [46] Underutilization of Combination Anti-TNF Therapy in Population-based Study
    Kurowski, Jacob A.
    Achkar, Jean-Paul
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (01) : 158 - 159
  • [47] Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
    Yzet, Clara
    Dupas, Jean-Louis
    Fumery, Mathurin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (05): : 748 - 749
  • [48] Objective measurement of response to anti-TNF therapy in psoriatic arthritis
    Abdullah, Shazia
    Marshall, Nicola J.
    Kane, David
    Platt, Phill
    Kay, Lesley J.
    RHEUMATOLOGY, 2008, 47 : II66 - II67
  • [49] Biomarkers for prognosis of response to anti-TNF therapy of rheumatoid arthritis
    Stuhlmueller, B.
    Skriner, K.
    Haeupl, T.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (09): : 812 - +
  • [50] Clinical, endoscopic and histological remission in paediatric chronically active ulcerative colitis after prolonged treatment with selective granulocyte-monocyte adsorptive apheresis
    Martin-Carpi, Javier
    Varea, Vicente
    JOURNAL OF CROHNS & COLITIS, 2009, 3 (03): : 216 - 217
12345